anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention belongs to the technical field of materials, and particularly relates to an open type hollow silicon nano capsule, and a preparation method and application thereof. The interior of the open type hollow silicon nanocapsule is of a cavity structure, and the exterior of the open type hollow silicon nanocapsule is of a silicon dioxide shell layer; the shell layer of the shell has a single 10-50 nm open pore structure. The size of the inner cavity of the open type hollow silicon nanocapsule is 220 +/-10 nm, and the thickness of the outer silicon dioxide shell layer is 15 +/-3 nm. The open type hollow silicon nanocapsule is spherical in shape, and the particle size is 254 +/-7 nm. The method has the advantages of simple preparation, low cost, good repeatability and uniform particle size, and can realize large-scale preparation. The open type hollow silicon nanocapsule prepared by the invention can be used as an animal vaccine delivery carrier.
A method for providing recommendations to a care provider includes receiving, by a monitoring system, environmental information regarding an environment in which a care provider is providing care to a recipient. The environmental information includes interaction data regarding interactions between the care provider and the recipient and entity data regarding entities in the environment. The method includes applying analytic analysis to the environmental information to generate input to a machine learning model. The input includes first features indicative of aspects of the interactions and second features indicative of one or more relations between the entities. The method includes determining a recommendation for the care provider that is predicted to facilitate achieving a goal associated with the recipient by applying the machine learning model to the input. The method includes providing the recommendation by the monitoring system to the care provider.
WSD0628 treatment should be started the day before radiation therapy starts (Day 1). Radiation therapy is given for 10 consecutive business days (Day 2-15, not including weekends and holidays), and WSD0628 will only be given on those 10 consecutive business days ≥30 minutes but ≤2 hours before radiation.
1285547 Hair-setting composition NATIONAL STARCH & CHEMICAL CORP 4 Aug 1970 [5 Aug 1969] 37536/70 Heading C3U [Also in Divisions C4 and D1] A hair setting composition comprises an aqueous dispersion containing 1-6%, by weight, of a cationically substituted starch of amylose content more than 50% by weight, the starch being selected from primary, secondary, tertiary or quaternary amine derivatives of starch containing 0À6-6% by wt. nitrogen; sulphonium derivatives having 1À2-12% by wt. sulphur; and phosphonium derivatives having 1À2-12% by wt. phosphorus. If, however, a non-cationic stabilizing group is included in the starch up to a maximum degree of substitution of 0À7, the amounts of N, P, and S may be reduced to 0À1, 0À2 and 0À2% respectively. A preferred starch derivative has the formula X-O-R-N-R 1 R 2 , where X is starch, R is alkylene or hydroxyalkylene and R 1  and R 2  are alkyl, aryl or alkaryl. The stabilizing group, if present, may be an ether or ester group. The hair setting composition is prepared by dispersing the starch derivative in cold water and heating to 90-100‹ C. for 20-30 minutes. The product may be then diluted to give a final starch content of 1-6%, by weight. The composition may be used in aerosol form, such that the composition contains 1-4% by weight starch (in aqueous dispersion), ethanol or iso. propanol, and an aerosol propellant, e.g. propane, butane, isobutane, trichloromonofluoromethane or dichlorotetrafluoroethylene.
Feedback from facial expressions is known to influence emotional experience. Treatment of muscles involved in facial expression of sadness, anger or anxiety with botulinumtoxin showed a quick, strong and sustained improvement in the symptoms of depression. As considerable proportion of patients do not sufficiently respond to existing treatment options. Especially in the elderly current treatments show limited response or are associated with side effects. Injections with BTA are considered as a very safe treatment without lasting side effects. The aim of the study is to investigate effectiveness of BTA in treating major depression in the elderly in a cross-over designed, placebo-controlled manner.
Approximately %10-15 of couples of reproductive age have infertility issues. Ovulation induction and in vitro fertilization (IVF) are the main treatments for infertility. With ovarian stimulation (OS), the efficiency of IVF has been increased by collecting more than one oocytes and thus providing more embryos. Multifollicular growth in OS may cause an increase in sex steroids and an early LH peak, thus premature ovulation. Pituitary suppression with certain drugs has been used to prevent premature ovulation.. Among these drugs, it has been observed that GnRH agonists can cause down-regulation, hypo-estrogenic symptoms, ovarian cyst formation and Ovarian Hyperstimulation Syndrome (OHSS), while antagonists may have side effects such as low oocyte count and high cycle cancellation. The use of progesterone preparations as an alternative to these drugs recently gained ground.

Data including age, BMI, the duration of infertility, the type of infertility, antral follicle count, serum day 3 FSH level, Serum anti-Müllerian hormone level, total gonadotropin dose, stimulation time, pituitary suppression starting day, duration of pituitary suppression, premature ovulation, number of total oocyte count, the number of total M2, the number of PN , the number of Day 5 blast, number of transferred embryos, endometrial thickness on the day of transfer will be recorded. When the follicle size reaches 13-14 mm, patients will be randomized into 3 groups. Group 1 (Cetrorelix: n=99, 0.25 mg/day subcutaneously), Group 2 (Medroxyprogesterone Acetate: n=99, 2x5mg/day orally) and Group 3 (Dydrogesterone: n=99, 3x10 mg/day orally). Human chorionic gonadotropin (hCG) will be used for trigger when at least 2 follicles' diameter reaches 17-18mm for ovulation. Thirty-six hours after the hCG injection, the patient's oocytes will be collected. During 2-5 days of embryo culture, embryo quality will be determined according to D.Gardner criteria (1999). Embryos will be frozen as blast on the 5th day and transferred to the frozen cycle to be planned within the next month. Clinical pregnancy rates will be recorded by performing a blood test for on the 12th day after the procedure.

The aim of this study is to evaluate the results of three different protocols for prevention of premature ovulation in ovarian stimulation cycles. All patients undergo IVF cycles are randomly divided in to three groups. The first group is cetrorelix, the second group is medroxyprogesterone acetate and the third group is dydrogesterone.
Colectomy is life-saving in patients with familial adenomatous polyposis (FAP) because cancer development is inevitable in individuals with this disease. In this study, we aimed to determine the incidence of incidental malignancy in surgical specimens from patients who underwent colectomy for FAP. The files of patients diagnosed with FAP who underwent surgery in our clinic between 2010 and 2020 were retrospectively reviewed. Definitive surgery was performed in patients with histopathological malignancy identified in colonoscopic biopsies in the preoperative period, while prophylactic surgery was performed in patients without malignancy. The incidence of incidental malignancy in histopathological specimens from patients who underwent prophylactic colectomy was determined. Prophylactic colectomy should be performed in patients with FAP, as colorectal cancer transformation is inevitable in these individuals. The possibility of incidental cancer identified via histopathological analysis of colectomy specimens should be kept in mind in these patients.
A group of poorly studied immune-mediated neurological syndromes are associated with antibodies against glutamic-acid decarboxylase (GAD-Ab). GAD is the rate-limiting enzyme for the synthesis of gamma aminobutyric acid (GABA) from glutamate and is expressed by inhibitory neurons of the central nervous system. Neurological syndromes with anti-GAD antibodies (GAD-Ab) are often non-paraneoplastic. They mainly include limbic encephalitis (LE), cerebellar ataxia (CA) and stiff-person syndrome (SPS). Although the pathogenic role of GAD-Ab is controversial, most patients have high serum levels and GAD-Ab are also detected in the cerebrospinal fluid (CSF) along with other inflammatory abnormalities such as oligoclonal bands. GAD-Ab may also be present in the serum of T1DM patients, as pancreatic beta cells also express GAD, but usually at much lower titers than those of neurological patients. Organ-specific autoimmune diseases, such as T1DM and autoimmune thyroid disease, are common among patients with GAD-Ab and neurological syndromes and in their relatives, suggesting a shared genetic predisposition to autoimmune disorders. This is also supported by family reports of neurological syndromes with GAD-Ab and some HLA associations described in SPS.

The aim of this study is to describe the different autoimmune organ-specific diseases present in patients with GAD-Ab and their relatives, along with to identify families with higher aggregation of autoimmune diseases and establish potential ways of inheritability.
FIELD: medicine, chemistry. SUBSTANCE: invention relates to preparing DNA-base antiviral preparations. DNA is extracted from animal raw. Method involved addition of chemical reagent to biogenic reaction mass containing DNA that ensures under mild condition to cleave glycoside bonds in nucleotides and obtain homogeneous native polymers at molecular mass 300-500 kDa, at ratio N/P from 1.0 to 1.5, at RNA content from 3.0 to 5.0%, at protein content from 0.7 to 1.5%, and metal content - 0.001%, not above. Obtained preparations do not show cytotoxicity and exhibit activity against HIV-virus, herpes-virus, adenovirus and influenza viruses. EFFECT: improved method of preparing.
Participants receive SCBT at a frequency of twice a week in the first 4 weeks, and once a week in the following 4 weeks. They also take SSRIs and/or SNRIs through the trial at a recommended dosage.
A stable immunogenic composition or vaccine comprising at least one antigen, wherein the antigen comprises a viral glycoprotein, and at least one adjuvant, wherein the adjuvant comprises sucrose fatty acid sulphate esters, and wherein the antigen and adjuvant are co-lyophilised. The composition may not comprise alum. The composition may comprise two or more antigens, wherein each antigen is specific to a different virus. Also claimed is a method of making a composition comprising at least two antigens specific to a different virus from the same or different families, and providing at least one adjuvant, wherein the adjuvant comprises sucrose fatty acid sulphate esters and not alum, wherein the antigens and adjuvant are co-lyophilised. The composition may be administered to a mammal for up to three separate occasions to protect the mammal from subsequent infections. Also claimed is a composition comprising at least two antigens and at least one adjuvant, wherein the adjuvant comprises sucrose fatty acid sulphate esters, and wherein each antigen is a viral glycoprotein specific to a different genus of filovirus. The viral glycoprotein may be from Marburg Marburgvirus (MARV), Sudan ebolavirus (SUDV), or Zaire ebolavirus (EBOV).
Poststroke patients often suffer from muscle atrophy in quadriceps muscle. Quadriceps muscle is essential for independent standing or ambulation after stroke. Quadriceps muscle consists of four different muscles: rectus femoris, vastus intermedius, vastus lateralis and medialis. The present study search for reliability for rectus femoris and vastus intermedius muscle thickness and cross-sectional area using rehabilitative ultrasound imagining. Longitudinal and transverse ultrasound imagining of the muscle thickness will be performed on both rectus femoris and vastus intermedius muscles for both extremities. The procedures will be repeated by two experts at two separate times (7-10 days). For sarcopenia measurement grip strength and DEXA measurements of the patients will be calculated. Totally 68 patients will be included in the study.
OBJECTIVE: This study aimed to evaluate the short-term and long-term efficacy of Mongolian medical warm acupuncture for sciatica caused by lumbar disc herniation (LDH).
PATIENTS AND METHODS: The patients diagnosed with sciatica caused by LDH were randomly divided into the warm acupuncture of the Mongolian medicine group (n = 42, warm acupuncture treatment), the sham acupuncture group (n = 38, sham acupuncture using blunt-tipped needles) and the conventional drug group (n = 40, ibuprofen sustained release capsule). All patients were treated for 4 weeks and followed up for 8 weeks. The visual analog scale for leg pain (VAS-LP), Mongolian medicine indicators (efficacy indicators), VAS for waist pain (VAS-WP) and the Mos 36-item short form health survey (SF-36) score were analyzed at baseline, after two-week treatment, after four-week treatment, at four-week follow-up and at eight-week follow-up.
RESULTS: Warm acupuncture treatment significantly decreased the VAS-LP and VAS-WP scores of patients at treatment and follow-up (p < 0.05), and pain was improved compared to the conventional drug group and sham acupuncture group. The total effective rate was markedly higher in the warm acupuncture of the Mongolian medicine group compared with the conventional drug group at 8-week follow-up (p < 0.05), but sham acupuncture treatment resulted in no evident improvement in the Mongolian medicine indicators. Additionally, at treatment and follow-up, warm acupuncture of the Mongolian medicine group showed a significant increase in the physical function, physical role, body pain, and emotional and mental health role scores of the SF-36 survey compared with the sham acupuncture groups.
CONCLUSIONS: Mongolian medical warm acupuncture effectively relieves leg and waist pain and improves the total therapeutic effect and the quality of daily life for patients with sciatica caused by LDH, with significant long-term efficacy. Our study provides a basis for warm acupuncture in the treatment of sciatica caused by LDH. Chinese Clinical Trial Registry ID: ChiCTR- INR-15007413.
No studies have been conducted to assess potential of bevacizumab products for carcinogenicity or mutagenicity.

Bevacizumab products may impair fertility. Female cynomolgus monkeys treated with 0.4 to 20 times the recommended human dose of bevacizumab exhibited arrested follicular development or absent corpora lutea as well as dose-related decreases in ovarian and uterine weights, endometrial proliferation, and the number of menstrual cycles. Following a 4- or 12-week recovery period, there was a trend suggestive of reversibility. After the 12-week recovery period, follicular maturation arrest was no longer observed, but ovarian weights were still moderately decreased. Reduced endometrial proliferation was no longer observed at the 12-week recovery time point; however, decreased uterine weight, absent corpora lutea, and reduced number of menstrual cycles remained evident.
Participants will either receive ibrutinib and RICE/RVICI background therapy or RICE/RVICI background therapy alone, until 3 cycles are completed or until PD or unacceptable toxicity during the treatment phase. Participants who received ibrutinib and RICE/RVICI background therapy and with PR or better only will receive ibrutinib alone for 3 cycles during post-treatment phase.
Provided are bifidobacterium breve B51 and B280, a product thereof, and use thereof. The bifidobacterium breve is B51 or B280. The B51 is collected in China General Microbiological Culture Collection Center of China Committee for Culture Collection of Microorganisms, with the collection number CGMCC No. 20679. The B280 is collected in China General Microbiological Culture Collection Center of China Committee for Culture Collection of Microorganisms, with the collection number CGMCC No. 20678. The bifidobacterium breve B51 and B280 can efficiently utilize fucosyl HMOs. Compared with conventional bifidobacterium breve M-16V capable of being used for infants, when the bifidobacterium breve B51 and B280 are used in combination with the fucosyl HMOs, a mutual promotion effect can be achieved, and the synbiotic effect of the bifidobacterium breve B51 and B280 and the fucosyl HMOs can be more accurately exerted, thereby achieving a synergistic effect.
FIELD: medicine. ^ SUBSTANCE: invention relates to crystalline forms of antibodies against EGF receptor, in particular, Mab C225 (cetuximab) and Mab h425 (EMD 72000), which as a result ensure obtaining biologically active antibody protein by dissolving or suspending in water medium. Such inventions relate to method of obtaining crystalline forms of anti- EGFR antibodies. Essence of method lies in the following: antibody and/or one of its versions and/or fragments, dissolved or suspended in water solution, are precipitated by means of precipitating agent. Invention also relates to pharmaceutical compositions, including at least one crystalline form of Mab C225 (cetuximab) or Mab h425 (EMD 72000), and optionally fillers and/or auxiliary substances and/or additional pharmaceutically active ingredients. ^ EFFECT: pharmaceutical compositions with antibodies Mab C225 (cetuximab) and Mab h425 (EMD 72000), obtained by dissolving or suspending in water medium have higher resistance to stress conditions, such as higher temperature, atmospheric humidity and do not contain toxic auxiliary substances. ^ 8 ex
A process for sealing hard gelatine capsules comprises spraying the previously filled and sealed hard gelatine capsules at 40-60 deg.C. in a fluidised bed dryer for 30 min. either (a) with only an aq. gelatine soln., or (b) with an aq. gelatin soln. contg. 5% talcum or 1% of a polyethylene glycol No. 5000-20000 or 3-5% of a synthetically prepd. amorphous, highly porous and pure silicic acid and then immediately drying. The process takes 30 min. and is carried out in a fluidised bed dryer. USE/ADVANTAGE - The process ensures safely and tightly sealed capsules without the need to bandroll the folds which would require special machines and without the need to use organic solvents (previously necessary). Conventional machines, which are usually present in most factories, can be used, even for small runs. The capsules can be given protective and regulating layers with specific biological functions (eg. stomach acid resistance and/or sustained release properties) after sealing. Using the silicic acid and gelatine soln., even capsules contg. oily and paste-like pharmaceuticals can be sealed. The process is environmentally friendly.
Carbon black nanoparticles (CBNPs) and cadmium (Cd) are major components of various air pollutants and cigarette smoke. Autophagy and inflammation both play critical roles in understanding the toxicity of particles and their components, as well as maintaining body homeostasis. However, the effects and mechanisms of CBNPs and Cd (CBNPs-Cd) co-exposure on the human respiratory system remain unclear. In this study, a CBNPs-Cd exposure model was constructed to explore the respiratory toxicity and combined mechanism of these chemicals on the autophagy-lysosome pathway in the context of respiratory inflammation. Co-exposure of CBNPs and Cd significantly increased the number of autophagosomes and lysosomes in human bronchial epithelial cells (16HBE) and mouse lung tissues compared to the control group, as well as the groups exposed to CBNPs and Cd alone. Autophagic markers, LC3II and P62 proteins, were up-regulated in 16HBE cells and mouse lung tissues after CBNPs-Cd co-exposure. However, treatment with Cq inhibitor (an indicator of lysosomal acid environment) resulted in a substantial decreased co-localization fluorescence of LC3 and lysosomes in the CBNPs-Cd combination group compared with the CBNPs-Cd single and control groups. No difference in LAMP1 protein expression was observed among the exposed groups. Adding 3 MA alleviated inflammatory responses, while applying the Baf-A1 inhibitor aggravated inflammation both in vitro and in vivo following CBNPs-Cd co-exposure. Factorial analysis showed no interaction between CBNPs and Cd in their effects on 16HBE cells. We demonstrated that co-exposure to CBNPs-Cd increases the synthesis of autophagosomes and regulates the acidic environment of lysosomes, thereby inhibiting autophagy-lysosome fusion and enhancing the inflammatory response in both 16HBE cells and mouse lung. These findings provide evidence for a comprehensive understanding of the interaction between CBNPs and Cd in mixed pollutants, as well as for the prevention and control of occupational exposure to these two chemicals.
An oral pharmaceutical multi-particulate dosage form comprising at least two populations of particles, a first population of opioid agonist particles and a second population of opioid antagonist particles and a method for producing the dosage form are described. The opioid agonist particles provide an analgesically effective amount of opioid agonist and the opioid antagonist particles provide an amount of opioid antagonist effective to attenuate side effects associated with chronic dosing of the opioid agonist. The first population of opioid agonist particles and the second population of opioid antagonist particles are visually indistinguishable, thereby reducing the potential for drug abuse of the opioid agonist by separation of the two particle populations. In accordance with particular aspects of the invention, the opioid agonist particles and opioid antagonist particles are each provided with sustained release membrane coatings capable of releasing the opioid agonist and opioid antagonist at proportionate rates over a dosing interval. The dosing interval may be at least about 8 hours and preferably from about 12-24 hours. The dosage form in accordance with particular embodiments of the present invention may further comprise a non-opioid analgesic, preferably in the form of immediate release or sustained release particles.
A hair treatment composition is described that contains an acetoacetylated compound. The acetoacetylated compound, for instance, can be a bis acetoacetylated compound. In one embodiment, for instance, the acetoacetylated compound comprises a bis acetoacetate or a bis acetoacetamide. In one embodiment, the hair treatment composition can be used to straighten hair. The composition is also well suited for decreasing hair frizz. The acetoacetylated compound is capable of crosslinking hair fibers upon the application of heat.
The high intensity intervention includes: navigated outreach, with four in-depth education outreach sessions; mailed FIT; education material; and follow-up mailed reminders (Group 1). The navigated outreach includes one-on-one information dissemination about CRC, importance of adhering to CRC screening guidelines, identification and solutions to screening barriers, motivation, self-efficacy and comprehension on how to complete the FIT kit, and gathering (if requested) and return of the completed FIT to the laboratory. The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.